Products
Latest Partnered Companies
Projects
Estimated Cost :
CAD$25 Million
Piramal Pharma Solutions Invests CAD$25 Million to Expand its Facility in Aurora, Canada
Pharma Solutions business to expand its Aurora facility in Canada with the addition
Estimated Cost :
US$109 million
Audentes Therapeutics to Build US$109 million Gene Therapy Manufacturing Facility
Audentes Therapeutics has announced its plans to build a new gene therapy
Estimated Cost :
US$272.69 million
Merck Invests in New Biotech Development Facility in Switzerland
Merck has invested US$272.69 million for the expansion of its Biotech Development Center
Estimated Cost :
$180 Million
Thermo Fisher Scientific to Expand its Capacity of Viral Vector Manufacturing in Plainville, Massach
Thermo Fisher Scientific to Expand its Capacity of Viral Vector Manufacturing in Plainville, Massach
Press Release
Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities for Facility in India
Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of contract biopharmaceutical manufacturing and development services, is pleased to announce a major expansion of its small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India. Construction of the 8,500 square meter facility began at the end of July 2020 and is expected to be completed by mid-2022.
UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.
UNION therapeutics A/S ("UNION") announced the completion of an agreement with TFF Pharmaceuticals, Inc. ("TFF") to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.
Beroni Group Signs Agreement with Genscript Biotech Corporation to Conduct Further Study to Develop Nanobody-based Medical Solution for COVID-19
Galapagos NV and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD).
Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property
Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced that it has taken assignment to certain microbial intellectual property, and has non-exclusively licensed foundational CRISPR-Cas9 intellectual property controlled by Caribou Biosciences, a leading CRISPR genome editing company, to expand its therapeutic pipeline and platform capabilities.
Events
Articles
Nanotechnology in Drug Delivery to Eyes, Skin, and Wounds Via Topical Route
One of the most favored courses for administering medications to eyes, skin, and wounds is the topical route. The principle objective for this
An Overview - Active Pharmaceutical Ingredient (API)
Active Pharmaceutical Ingredient (API) is the term used to refer to the biologically active component of a drug product
Next-Generation Biological Therapeutics Discovery & Development
Next-Generation Biological Therapeutics Discovery & Development
AI, Big Data to Have \'Greatest Technology Impact\' in Pharma Industry in 2019
AI, Big Data to Have \'Greatest Technology Impact\' in Pharma Industry in 2019
Dividella’s Monomaterial Packaging Solution to the Global Plastics Crisis
Dividella’s Monomaterial Packaging Solution to the Global Plastics Crisis
Expert Talk
Testimonials
I have read it with interest. I think it could be of interest to managers and professionals in Asia's Pharma companies as well as global companies that wish to learn more about how to do business--from R&D to marketing-in Asia.
Baoping Wang - Research Director
Novo Nordisk (China) R&D Centre
Advertisements
See your banner here...
